

DAFTAR PUSTAKA

- Adham M., *et al.* 2012. Nasopharyngeal Carcinoma in Indonesia: Epidemiology, Incidence, Signs, and Symptom at Presentation. *Chin J Cancer* ; 31(4): 1-12.
- Akuntanto I. 2014. Hubungan Rasio Netrofil Terhadap Limfosit Dengan Stadium Klinis Pada Karsinoma Nasofarings. Fakultas Kedokteran Universitas Gadjah Mada Yogyakarta.
- Almog N, *et al.* 2006. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. *FASEB*;20:947-9. 10.1096/fj.05-3946fje
- Aprilia W, *et al.* 2017. Hubungan Perubahan Rasio Neutrofil-Limfosit (RNL), Rasio Limfosit-Monosit (RLM) dan Rasio Trombosit-Limfosit (RPL) Dengan Stadium Tumor, Nodul, Metastasis Pada Pasien Karsinoma Nasofaring Fakultas Kedokteran Universitas Sumatera Utara Medan.
- Astuti R, Sukeksi A. 2018. Perbedaan jumlah limfosit sebelum dan sesudah kemoterapi pada penderita *ca mammae*. Universitas Muhammadiyah Semarang.
- Bambace, NM., Holmes, CE. 2011. The Platelet Contribution to Cancer Progression, *Journal of Trombosis and Haematology*, Vol 9, p; 237-249.
- Bardash Y, *et al* 2019. Trombosit-Lymphocyte Ratio as a Predictor of Prognosis in Head and Neck Cancer: A Systematic Review and

- Meta-Analysis. *Oncol Res Treat* ;42:665-677. doi: 10.1159/000502750
- Barnes, L., Eveson, J.W., Reichart, P., et al. 2005, World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. IARC Press, Lyon.
- Barrett-Lee P, et. al., 2005. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the european cancer anemia survey. *The Oncol* 10: 743–57
- Bastid J, et al. 2014. Lymphocyte-derived interleukin17A adds another brick in the wall of inflammation-induced breast carcinogenesis. *Oncoimmunology* ;3:e28273.
- Chan, ATC., *et al.* 2012. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment, and follow up. *Annals of Oncology* : 23(7); 83-85.
- Chen JH, Huang WY, Ho CL, et al. 2019. Evaluation of oral tegafur-uracil as metronomic terapi following concurrent chemoradioterapi in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. *Head Neck* ;41:3775-82. 10.1002/hed.25904
- Chen KJ, Zhou L, Xie HY, et al. 2012. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. *Med Oncol* ;29:1817–26
- Chen S, at al. 2016. The preoperative trombosit–lymphocyte rasio *versus* neutrophil–lymphocyte rasio: which is better as a prognostic factor

in oral squamous cell carcinoma?. In : *Therapeutic Advances in Medical Oncology* Vol. 8(3) 160–167.

Chen YP, Chen C, Mai ZY, et al. 2015. Pretreatment trombosit count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. *Oncol Lett* ; 9(3):1458-1466. doi:10.3892/ol.2872

Cen dan Li. 2019. Trombosit to lymphocyte rasio as a potential prognostic factor in nasopharyngeal carcinoma In: journal medicine. China.

Dhingra PL dan Shruti D. 2014. Disease of Ear, Nose, and Throat & Head and Neck Surgery. 6th ed. India: Elseiver, pp 238-240, 250-252.

D. Sharma, K. E. Et al. 2014. “Trombosits in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer,” *Journal of Cellular Physiology*, vol. 229, no. 8, pp. 1005–1015.

Faiza, S., Sukri R., dan Aswiyanti A. 2016. Karakteristik klinis dan patologis karsinoma nasofaring di bagian THT-KL RSUP Dr.M. Djamil Padang. *Jurnal kesehatan Andalas* ; 5(1)

Fung, S., et al. 2016. Clinical utility of circulating Epstein-barr virus DNA analysis for the management of nasopharyngeal carcinoma. *Chin Clin Oncol* ; 5(2): 1-8.

Hamita, Kentjono WA, Wiyadi H. 2020. Correlation between IL-10 Expression with Histopathology Type on Nasopharyngeal Carcinoma Patients . *Medico-legal Update*, April-June 2020, Vol. 20, No. 2

- Hartono, Et Al. 2015. Penilaian Jumlah Neutrofil, Limfosit Dan Trombosit, Kadar Protein Reaktif C, Kadar Albumin, Rasio Neutrofil Limfosit, Serta Rasio Trombosit Limfosit sebelum dan setelah terapi pada Penderita karsinoma payudara. *Jurnal biomedik (jbm)*, volume 7, nomor 3, hlm.163-170.
- Hasibuan NR, Farhat F, Haryuna TS, Yudhistira A. 2014. Korelasi positif ekspresicyclooxygenase-2 dengan microvessel density pada karsinoma nasofaring. *Oto Rhino Laryngologica Indonesian* ;44(1):34-43. DOI: <https://doi.org/10.32637/orli.v44i1.81>
- He S. Et al. 2017. Plasma Fibrinogen Correlates with Metastasis and is Associated with Prognosis In : Human Nasopharyngeal Carcinoma. In : *Journal of Cancer* ; 8(3): 403-409.
- J. Gay, Brunhilde Felding-Habermann. 2011. Contribution of Platelets to Tumor Metastasis Laurie. *Nat Rev Cancer.*;11(2):123–134. doi:10.1038/nrc3004
- Jiang, Rou; et al. 2015. *The elevated pretreatment trombosit-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients. Tumor Biology, 36(10), 7775–7787.* doi:10.1007/s13277-015-3505-0.
- Kam, M., et al. 2013. Current controversies in radioterapi for nasopharyngeal carcinoma (NPC). *Oral Oncology* : 1-6
- Kementerian Kesehatan. 2013. Panduan Penatalaksanaan Kanker Nasofaring. *Kementerian Kesehatan Republik Indonesia* .

- Kolegium Ilmu Kesehatan THT-KL, 2010. Karsinoma Nasofaring, Modul Onkologi . 1-51.
- Kong Yew, et al. 2018. Neutrophil---lymphocyte rasios in the prognostication of primary non-metastatic nasopharyngeal carcinoma. In : Braz J Otorhinolaryngol. 84(6) :764-771.
- Kuhuwael F.G., 2010. Perbandingan Kasus Kanker Kepala Leher dalam Dua Dekade di Makassar. Makalah disajikan dalam KONAS PERHATI XV Makassar 3-5 Juli 2010.
- Kundu, J.K., Surh, Y.J., 2008. Inflammation: Gearing the journey to cancer. *Mutation Research*. 659:15–30.
- Lee, A., et al. 2015. Management of nasopharyngeal carcinoma: current practice and future perspective. *J Clin Oncol* : 1-10.
- Liao Q, Guo X, Li X, Li X, Chen P, et al. 2012. Analysis of the contribution of nasopharyngeal epithelial cancer cells to the induction of a local inflammatory response. *J Cancer Res Clin Oncol*. 2012 Jan; 138(1):57-64.
- Lippitz BE. 2013. Cytokine patterns in patients with cancer: a systematic review. *Lancet Oncol*;14:e218–28
- Li jianpei, et al. 2018. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics, In: *International Journal of Biological Sciences* ; 14(5): 549-556.
- Longo, D. L. and York, N. 2010, 'Harrison's Hematology and Oncology.'

- Ma, X. et al. 2014, 'Prognostic significance of thrombocytosis, trombosit parameters and aggregation rates in epithelial ovarian cancer', *Journal of Obstetrics and Gynaecology Research*, vol. 40, no. 1, pp. 178–183. doi: 10.1111/jog.12151.
- Natalia L. Et al. 2016. Hubungan Rasio Trombosit Terhadap Limfosit Dengan Stadium Klinis Karsinoma Nasofaring.
- Noviyani, R. et al. 2019. 'Effect of paclitaxel-cisplatin kemoterapi towards hemoglobin , trombosit , and leukocyte levels in epithelial ovarian cancer patients', 9(01), pp. 104–107. doi: 10.7324/JAPS.2019.90115.
- Oh, J. et al. 2014, 'Preoperative Thrombocytosis Is an Independent Poor Prognostic Factor in Patients with Epithelial Ovarian Cancer', *Clinical & Experimental Thrombosis and Hemostasis*, vol. 1, no. 1, pp. 17–21. doi: 10.14345/ceth.14006.
- Paier, F., et al. 2012. Role of kemoterapi in nasopharyngeal carcinoma. *Oncology review*,: 6(1); 1-6
- Pan, Xing-Xi; et al. 2019. *Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients. The Laryngoscope*, (), lary.28099–. doi:10.1002/lary.28099
- Pastor, M., et al. 2018. SEOM clinical guideline in nasopharynx cancer. *Clin Transl Oncol* : 20; 84-88
- Petersson BF, et al. 2017. Nasopharyngeal carcinoma. Dalam: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slotweg PJ (eds). WHO

clasification of head and neck tumours. Edisi ke 4. Lyon: IARC. H. 65-70.

Puspitasari, D. 2011. Gambaran karsinoma nasofaring di RSUP H. Adam Malik Medan Tahun 2006-2010. Tesis. Medan: Magister Universitas Sumatera Utara.

Roezin A, Adam M. Karsinoma nasofaring. 2007. Dalam: Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD, penyunting. Buku Ajar Ilmu Kesehatan THT Kepala & Leher. Edisi ke-7. Jakarta: Balai Penerbit FKUI;h. 182-87.

Ruuskanen M, et al. 2017. Outcome of nasopharyngeal carcinoma in Finland: A nationwide study. *Acta Oncol* ;57:251-6. 10.1080/0284186X.1346378.

Sacher RA, McPherson RA, Brahm U Pendit, 2009. Metode Hematologi. Dalam: Tinjauan Klinis Hasil Pemeriksaan Laboratorium. Jakarta. EGC : 54-6.

Santosa, BS., Bakti S., dan Widodo AT. 2009. Radioterapi pada Karsinoma Nasofaring. *Jurnal THT-KL Universitas Airlangga* : 12(3); 134-141

Siala, W., et al. 2014. Late Toxicities after Conventional Radioterapi for Nasopharyngeal Carcinoma: Incidence and Risk Factors. *Journal of Radioterapi Hindawi* : 1-8.

Symond, P., et al. 2012. Walter & Miller's Textbook of Radioterapi, Radiation physic, terapi and oncology. 7th ed. London: Elsevier. pp 280

- Tabuchi, K., *et al.* 2011. Early detection of Nasopharyngeal Carcinoma: Review Article. *Hindawi*, : 1-7.
- Tao, Q. dan Anthony C. 2007. nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. *Cambridge University Press*, : 9(12); 1-25
- Tsao, S., *et al.* 2014. etiological factors of nasopharyngeal carcinoma. *Oral Oncology* : 50; 330-338.
- Wang N, et al . 2019 .Prognostic value of pretreatment inflammatory biomarkers in primary small cell carcinoma of the esophagus. *Thoracic Cancer* . Department of Radiation Oncology, Zhengzhou University, Zhengzhou, China.
- Wei, W., dan Dora K. 2010. Current Management Strategy of Nasopharyngeal Carcinoma. *Clinical and Experimental Otorhinolaryngolog* :3(1); 1-12
- Wijaya F. Dan Bogi S. 2017. Deteksi dini dan diagnosis karsinoma nasofaring. *CDK-254*, 44(7).
- Wolden SL. 2001. Cancer of the Nasopharynx. In: Jatin P. Shah, ed. *Atlas of Clinical Oncology - Cancer of the Head and Neck*. Vol London: BC Decker Inc; 146-155.
- Wu SG, Lian CL, Wang J, et al. 2019. The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up. *Ann Transl Med*. 2019;7(23):768. doi:10.21037/atm .11.75

- Yang S, et al. 2019. Prognostic Significance of Hematological Markers for Patients with Nasopharyngeal Carcinoma. In : Journal of Cancer ; 10(11): 2568-2577.
- Yao et al. 2019. Prognostic value of neutrophil to lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. BMC Cancer 19:37.
- Ye Lu, et al. 2018. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. European Archives of Oto-Rhino-Laryngology), 275:1309–1317
- Zeng M dan Yi-Xin Z. 2010. Pathogenesis and Etiology of Nasopharyngeal Carcinoma In: Nasopharyngeal cancer, multidisciplinary management. Lu, JJ., Cooper JS., dan Lee, AWM (ed). China.
- Zulkarnain I, et al. 2017. Penurunan Hemoglobin, Neutrofil, Dan Trombosit Pascakemoterapi Cisplatin-Paclitaxel Pada Penderita Tumor Ganas Kepala Dan Leher . Ural Tht - KI Vol.10, No.1, Hlm. 1 – 10.

LAMPIRAN

Lampiran 1. Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed,PHD, SpCK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 424/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 12 Agustus 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20050211	No Sponsor Protokol	
Peneliti Utama	dr. Aksimitayani	Sponsor	
Judul Peneliti	Hubungan Rasio Trombosit Limfosit Dengan Gambaran Histopatologi Sebelum Dan Setelah Kemoterapi Dengan Atau Tanpa Radioterapi Pada Karsinoma Nasofaring		
No Versi Protokol	1	Tanggal Versi	18 Mei 2020
No Versi PSP	1	Tanggal Versi	18 Mei 2020
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo dan RS Universitas Hasanuddin serta RS Jejaring di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 12 Agustus 2020 sampai 12 Agustus 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Data Dasar Hasil Penelitian

NO	Nama	JK	RM	Regimen kemo	siklus1				siklus2				siklus3				after siklus3			Tipe PA	Limfosit absolute				Platelet limfosit ratio											
					plt	lim	wbc	stadium	T	N	plt	lim	wbc	stadium	T	N	plt	lim	wbc		stadium	T	N	plt	lim	wbc	limA1	limA2	limA3	limA4	PLR1	PLR2	PLR3	PLR4		
1	KU	perempuan	810641	brev-el-cisplatin	239	11	10	2	2	0	361	15,6	8,1	2	2	0	271	13,9	8,7	3	2	0	221	25,3	7,2	2	1	3	1,08	1,26	1,21	1,82	219,2661	265,6917	224,0966	121,3219
2	JU	perempuan	900503	pacl-carbo	408	11	8,9	4	1	3	587	14,1	11,7	4	1	3	391	16,1	6,6	4	1	3	378	32,1	4,6	2	1	2	0,96	1,65	1,06	1,48	424,4694	355,8223	367,9654	255993,5
3	MS	Laki-laki	795259	pacl-cis	308	17	11	4	4	0	308	32,5	8,9	4	4	0	185	52,7	7,8	4	4	0	282	36,6	6,9	2	1	2	1,77	2,89	4,11	2,53	173,9916	106,4823	45,0056	111665,3
4	RU	Laki-laki	903697	pacl-cis	334	19	16	4	2	3	412	32,2	9,5	4	2	3	291	41,7	5,1	4	2	3	174	47	4,5	2	1	2	3,03	3,06	2,13	2,12	110,1656	134,6845	136,8317	82269,5
5	HM	perempuan	910305	pacl-carbo	647	35	14	2	2	0	424	29,3	7,5	2	2	0	309	54,3	5,4	2	2	0	152	45,1	4,1	2	1	2	4,95	2,20	2,93	1,85	130,7652	192,9465	105,3816	82202,15
6	MU	Laki-laki	909719	pacl-carbo	330	13	11	3	3	2	529	18,3	7,1	3	3	2	275	4,3	27,6	3	3	2	256	5,6	20	2	1	2	1,49	1,30	1,19	1,12	221,8637	407,1423	231,7155	228571,4
7	SA	Laki-laki	914423	brev-el-carbo	505	22	11	3	3	1	405	20	11	3	3	1	526	9,6	12,9	3	3	0	369	19,3	9,4	2	1	1	2,40	2,20	1,24	1,81	210,6976	183,9989	424,7416	203395,4
8	BA	Laki-laki	884869	pacl-carbo	275	22	5,5	2	2	1	235	9,9	12,8	2	2	1	236	10,2	13,8	3	2	1	253	11,4	10,8	2	1	3	1,22	1,27	1,41	1,23	225,2252	185,4482	167,6613	208490,6
9	LU	perempuan	877936	pacl-carbo	216	23	6,5	2	1	1	209	38,9	4,3	2	1	1	128	16,1	11,1	2	1	1	137	17,7	12,3	2	1	2	1,46	1,67	1,79	2,18	147,6923	124,9477	71,6242	62927,75
10	JS	perempuan	883689	pacl-cis	516	20	10	4	1	3	406	29	5,9	4	1	3	414	29,1	6,6	3	1	2	302	15,9	7,7	2	1	1	2,05	1,71	1,92	1,22	251,6705	237,2881	215,5576	246671,6
11	WS	perempuan	806795	pacl-carbo	430	32	9,7	4	1	3	347	43,6	8,4	4	1	3	212	53	6,4	4	1	3	212	53	6,9	2	1	2	3,07	3,66	3,39	3,66	139,8419	94,74681	62,5	57971,01
12	YB	Laki-laki	873515	brev-el-carbo	444	16	11	4	3	3	266	66,3	1,8	4	3	3	310	72	4,5	3	3	2	310	72	5,5	2	1	1	1,76	1,19	3,24	3,96	252,5023	222,8926	95,67901	78282,83
13	JM	Laki-laki	877356	brev-el-carbo	302	28	9,4	4	2	3	305	27	6,7	4	2	3	367	55,7	3,7	4	2	3	285	23,2	10,1	2	1	2	2,61	1,81	2,06	2,34	115,5671	168,6014	178,0775	121628,5
14	AK	Laki-laki	887080	pacl-cis	281	25	9,5	3	2	2	402	39,1	5,3	3	2	2	242	40,9	6,1	3	2	2	295	43,2	4,5	2	1	2	2,40	2,07	2,49	1,94	116,9128	193,9874	96,99788	151749
15	YK	Laki-laki	884494	pacl-carbo	316	17	8,2	2	2	1	371	33	4	2	2	1	305	46,1	2,7	2	2	1	326	26,6	4,7	2	1	2	1,40	1,32	1,24	1,25	225,3601	281,0806	245,039	280758,3
16	JL	Laki-laki	870961	pacl-cis	281	21	9,2	4	4	0	251	48,4	6,2	4	4	0	329	25,1	6	4	4	0	323	25,1	6,1	2	1	2	1,91	3,00	1,51	1,53	146,8436	83,64436	218,4959	210959,4
17	PI	Laki-laki	888693	pacl-cis	214	14	8,4	3	3	1	272	21,3	7,5	3	3	1	258	34,2	5,6	3	3	1	304	33	5,7	2	1	2	1,14	1,60	1,92	1,88	187,3249	170,266	134,7118	161616,2
18	SS	Laki-laki	866607	pacl-cis	212	30	7,5	4	4	1	247	39,6	7,2	4	4	0	147	44,1	6,5	4	4	0	199	40,4	5,8	2	1	1	2,21	2,85	2,87	2,34	95,81921	86,63019	51,28205	84926,6
19	PW	Laki-laki	905139	pacl-cis	302	87	22	3	2	2	400	22,2	6,1	3	2	2	306	16,8	9,5	3	2	2	331	16,6	8,3	2	1	2	1,88	1,35	1,60	1,38	160,7607	295,3773	191,7293	240238,1
20	IN	Laki-laki	918811	pacl-cis	251	65	2,8	3	3	0	453	44,8	6,6	3	3	0	200	13	6,6	3	3	0	187	17,3	8,4	2	1	2	1,83	2,96	0,86	1,45	137,2785	153,2062	233,1002	128681,5
21	SD	Laki-laki	867266	pacl-cis	229	32	9,1	3	3	1	280	43,5	3,5	3	3	1	281	53	4,3	3	3	1	338	47,5	4,4	2	1	2	2,94	1,52	2,28	2,09	77,90971	183,908	123,2997	161722,5
1	DR	perempuan	819694	pacl-cisplatin	450	9,3	4,9	1	1	0	355	12	6,5	1	0	424	17,2	5	3	1	0	324	23,3	1,8	3	2	3	0,46	0,78	0,86	0,42	987,4918	455,1282	493,0233	772,5322	
2	MR	Laki-laki	897586	pacl-cisplatin	280	18	12	4	2	3	268	37,4	6	3	2	2	192	49,5	6	2	2	1	211	51,6	5,8	3	2	1	2,14	2,24	2,97	2,99	131,0984	119,4296	64,64646	70,50254
3	MD	Laki-laki	875588	brev-el-carbo	378	14	9,7	4	3	3	368	35,6	7,4	3	3	2	276	46,3	5,7	2	2	2	204	32,2	6,9	3	2	1	1,33	2,63	2,64	2,22	284,4458	139,6903	104,5811	91,81745
4	BS	perempuan	898532	pacl-cis	468	36	7,7	3	3	0	346	48,1	8,4	3	3	0	210	24,5	15,9	3	3	0	277	56,5	4,9	3	2	2	2,73	4,04	3,90	2,77	171,2091	85,63509	53,90836	100,0542
5	SY	Laki-laki	793296	pacl-carbo	274	20	7,6	3	3	1	144	52,6	3,6	3	3	1	169	27,3	4,9	3	3	1	100	63,5	2,7	3	2	2	1,50	1,89	1,34	1,71	183,0083	76,04563	126,3362	58,32804
6	AMB	Laki-laki	859322	brev-el-carbo	273	24	8,5	4	4	0	371	21,8	14,2	4	4	0	251	45,1	5,4	4	4	0	375	11,8	13,3	3	2	2	2,07	3,10	2,44	1,57	131,6287	119,8475	103,0322	238,9448
7	IWI	perempuan	881879	pacl-cis	350	22	10	3	1	2	281	4,9	5,1	3	1	2	276	33	4,6	3	1	1	347	9,4	11,1	3	2	1	2,16	0,25	1,52	1,04	162,037	1124,45	181,8182	332,5666
8	FP	Laki-laki	870888	pacl-cis	383	17	9	3	3	0	360	46,3	4,9	3	3	0	326	15,7	8	3	3	0	418	18,6	10,9	3	2	2	1,52	2,27	1,26	2,03	251,808	158,6812	239,5341	206,1754
9	AD	perempuan	876935	pacl-cis	402	15	12	3	3	2	548	20,2	11,2	3	3	2	325	25,9	6,6	3	3	2	279	28	6,5	3	2	2	1,75	2,26	1,71	1,82	230,1878	242,2207	190,1252	153,2967
10	YS	Laki-laki	864065	pacl-cis	479	16	16	2	2	0	518	31,6	7,1	2	2	0	304	32	8,7	2	2	0	207	59,4	3	3	2	2	2,61	2,24	2,78	1,78	183,6636	230,8789	109,1613	116,1616
11	FM	perempuan	895405	pacl-cis	267	13	12	2	2	1	281	20,4	8,4	2	2	1	265	26,8	4,9	2	2	1	183	33,5	4,8	3	2	2	1,47	1,71	1,31	1,61	181,3859	163,9823	201,7971	113,806
12	YB	Laki-laki	887588	brev-el-carbo	406	9,2	19	4	4	0	488	41,1	6,3	4	4	0	361	31,2	6,4	4	4	0	297	30,1	7,4	3	2	2	1,72	2,59	2,00	2,23	235,9916	188,4679	180,7893	133,3393
13	MR	Laki-laki	883229	pacl-cis	374	19	11	2	1	1	265	20,1	11,5	2	1	1	183	23,5	7,7	2	1	1	274	27,3	6,4	3	2	2	2,01	2,31	1,81	1,75	186,1808	114,6442	101,1329	156,8223
14	ST	perempuan	876015	pacl-cis	513	15	5,5	2	1	1	597	24	7,9	2	1	1	483	12,7	7	2	1	1	397	11,1	9,6	3	2	2	0,82	1,90	0,89	1,07	625,9915	314,8734	543,3071	372,5601
15	IWI	Laki-laki	877766	pacl-carbo	368	12	11	2	2	1	355	9,5	8,7	2	2	1	457	20,8	6,4	2	2	1	259	33,7	5,6	3	2	2	1,36	0,83	1,33	1,89	271,2664	429,5221	343,2993	137,2404
16	AD	Laki-laki	861194	pacl-cis	519	59	12	3	2	2	435	30,2	7,5	3	2	2	455	32	5,7	3	2	2	388	40,3	5	3	2	2	6,80	2,27	1,82	2,02	76,35048	192,053	249,4818	197,5186
17	SD	Laki-laki	875215	pacl-cis	332	7,3	13	3	2	2	437	32	3,9	3	2	2	178	10,6	6	2	2	1	344	48,6	2,6	3	2	1	0,97	1,25	0,64	1,26	341,9508	350,1603	279,8742	272,2381
18	STO	Laki-laki	884712	brev-el-carbo	447	18	9,4	3	3	1	458	29,5	7,2	3	3	1	360	14,8	12	4	3	3	327	24,6	6,8	3	2	3	1,70	2,12	1,78	1,67	262,7248	215,6309	202,7027	195,4806
19	BK	Laki-laki	864193	brev-el-carbo	480	17	9,9	4	4	0	411	16,3	16,1	4	4	0	339	31	9	4	4	0	300	32,5	9,1											

Lampiran 3. Dokumentasi Penelitian

